Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib and SHR2554 in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT06712173Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of linperlisib and zeprumetostat in peripheral T-cell lymphoma (PTCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
linperlisibzeprumetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06712173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712173.